Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Result of General Meeting

19th Oct 2020 10:12

RNS Number : 4731C

Ergomed plc

19 October 2020

Ergomed Plc

Result of General Meeting

Guildford, UK - 19 October 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that at its General Meeting held today the special resolutions regarding the proposed Capital Reduction were passed with 100% shareholder approval (see table and notes below).

The Capital Reduction remains subject to the Court's approval and a directions hearing is scheduled for 28 October 2020. If the Court is satisfied that the application should proceed, a second hearing will be held on 10 November 2020 to confirm the Capital Reduction.

A further announcement will be made following the Capital Reduction becoming effective.

Terms used but not defined in this announcement are as defined in the Company's announcement of 1 October 2020.

Details of the voting in respect of each resolution are shown in the table below:

	For		Against		Withheld
Resolution	No. of Shares	%	No. of Shares	%	No. of Shares
1. To cancel the Company's Share Premium Account	41,339,888	100	2,000	0	1,414
2. To capitalise the Company's Merger Reserve by paying up B Shares	41,339,888	100	Nil	0	3,414
3. To cancel the B Shares	41,339,888	100	Nil	0	3,414

Notes:

1. Votes "For" and "Against" are expressed as a percentage of votes received.

2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3. Percentages in relation to Resolution 1 are rounded.

ENDS

Enquiries:

Ergomed plc	Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)

Numis Securities Limited	Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)

Consilium Strategic Communications - for UK enquiries	Tel: +44 (0) 20 3709 5700
Chris Gardner / Sue Stuart	[email protected]
Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMGCBDGCGBDGGC

Related Shares:

FTSE 100 Latest

Value8,463.46

Change46.12